trans,trans-Mycomycin (trans,trans-Trideca-3,5,7,8-tetraen-10,12-diin-1-saeure) | 544-51-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: trans,trans-Mycomycin (trans,trans-Trideca-3,5,7,8-tetraen-10,12-diin-1-saeure)
• CAS: 544-51-4；92379-02-7；143789-07-5
• 化学式: C₁₃H₁₀O₂
• 分子量: 198.221
• InChiKey: APNPVBXEWGCCLU-BNFZFUHLSA-N

物化性质

• 熔点：
  7.5° (deflagrates)
• 比旋光度：
  D25 -130° (c = 0.4 in ethanol)
• 沸点：
  402.9±38.0 °C(Predicted)
• 密度：
  1.075±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  5-(N-methyl-anilino)-penta-2,4-dienal 在 aluminium amalgam 、 硫酸 、 sodium methylate 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醚 为溶剂， 生成 trans,trans-Mycomycin (trans,trans-Trideca-3,5,7,8-tetraen-10,12-diin-1-saeure)
  参考文献：
  名称：

  Bohlmann,F.; Sucrow,W., Chemische Berichte, 1964, vol. 97, p. 1846 - 1856

  摘要：

  DOI：

文献信息

• FATTY ACID CONJUGATES OF QUETIAPINE, PROCESS FOR MAKING AND USING THE SAME
  申请人：KemPharm, Inc.

  公开号：US20170247368A1

  公开（公告）日：2017-08-31

  The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.

  目前所描述的技术提供了一种新型的奎硫平前药类，可以通过将脂肪酸与奎硫平进行化学共轭来合成。同时，还提供了制备本技术共轭物的药物组合物和方法。还提供了使用本技术组合物治疗患者的方法。
• An intravenous nutrient
  申请人：UNITIKA LTD.

  公开号：EP0100382A1

  公开（公告）日：1984-02-15

  The present invention is an intravenous nutrient which contains a fatty acid ester of carbohydrate and water. The nutrient fluid contains a carbohydrate component and a fat component. has an excellent stability in solution, and is used in nutrient fluid therapy for individuals who cannot take food orally. The nutrient fluid is especially suitable as a high calorie intravenous nutrient.

  本发明是一种静脉营养液，含有碳水化合物和水的脂肪酸酯。该营养液含有碳水化合物成分和脂肪成分，在溶液中具有极佳的稳定性，可用于无法口服食物的人的营养液治疗。该营养液尤其适合作为高热量静脉营养液。
• Polyacetylenes
  申请人：Gorinsky, Conrad

  公开号：EP0610059A1

  公开（公告）日：1994-08-10

  A 2-(1-nonen-3,5,7-triynyl)3-hydroxy tetrahydropyran (cunaniol) particularly that having the formula:- or a corresponding anhydrocunaniol or cunanione, for use in therapy, especially as a reversible heart blocking agent or neuromuscular active or in neurofunction generally; or for use as a pesticide or mycobactericide. Derivatives are also referred to as are various methods, e.g. of treatment, using the cunaniol, anhydrocunaniol, cunanione or derivatives.

  一种 2-(1-壬烯-3,5,7-三炔基)3-羟基四氢吡喃(cunaniol)，特别是具有以下式子的四氢吡喃(cunaniol) 或相应的茴芹二醇或茴芹二酮，用于治疗，特别是作为可逆性心脏阻断剂或神经肌肉活性剂，或一般用于神经功能；或用作杀虫剂或杀霉菌剂。此外，还提到了各种衍生物，例如使用胭脂虫酰、氢胭脂虫酰、胭脂虫硫酮或衍生物进行治疗的方法。
• RADICAL REACTION INHIBITORS, METHOD FOR INHIBITION OF RADICAL REACTIONS, AND USE THEREOF
  申请人：Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

  公开号：EP1541660A1

  公开（公告）日：2005-06-15

  The present invention has an object to provide a radical reaction inhibitory agent for inhibiting unsaturated compounds from decomposing through radical reactions, a method for inhibiting the formation of free radicals from unsaturated compounds and radical reactions thereof, and a composition which is suppressed in radical formation, radical reaction, or progress thereof. The object is solved by establishing a radical reaction inhibitory agent containing as an effective ingredient cyclotetrasaccharide or a mixture of cyclotetrasaccharide and its saccharide derivative(s), a method for inhibiting the formation of free radicals from unsaturated compounds and radical reactions thereof, and a composition which contains the agent and which is suppressed in radical formation, radical reaction, or progress thereof.

  本发明的目的是提供一种抑制不饱和化合物通过自由基反应分解的自由基反应抑制剂，一种抑制不饱和化合物自由基的形成及其自由基反应的方法，以及一种抑制自由基形成、自由基反应或其进展的组合物。本发明的目的是通过建立一种含有环四糖或环四糖及其糖衍生物混合物作为有效成分的自由基反应抑制剂、一种抑制不饱和化合物自由基的形成及其自由基反应的方法，以及一种含有该抑制剂并能抑制自由基的形成、自由基反应或其进展的组合物来实现的。
• SYNNOTCH RECEPTOR-REGULATED EXPRESSION OF IL12
  申请人：Carsgen Therapeutics Co., Ltd.

  公开号：EP3741861A1

  公开（公告）日：2020-11-25

  A binary vector and the provision of expression of a target antigen-dependent regulatory cytokine using the synNotch technology, so as to partially release the cytokine to enhance the function of T cell and reduce the non-specific toxic and side effect of the cytokine. A synthetic notch receptor is used to construct plasmid vectors to achieve local cytokine secretion. One plasmid vector uses a specific antibody as an extracellular domain for identifying a target antigen, a notch core comprises a transmembrane domain and a specific enzyme cutting site on a notch receptor, and transcription factor GAL4VP64 is used as an intracellular domain. When the target antigen is identified, the enzyme cutting site on the notch will be identified by a corresponding enzyme to hydrolyze and cut the intercellular transcription factor GAL4VP64. Another plasmid vector carries DNA identification/binding domain GAL4UAS of transcription factor GAL4 and correspondingly activates a minimal promoter of a target gene, and after being hydrolyzed and cut, GAL4VP64 will be bound to the binding domain to activate transcription of subsequent genes so as to express IL12 and secrete same out of the cell.

  一种二元载体，利用 synNotch 技术提供靶抗原依赖性调节细胞因子的表达，从而部分释放细胞因子，增强 T 细胞的功能，减少细胞因子的非特异性毒副作用。合成缺口受体用于构建质粒载体，以实现局部细胞因子分泌。一种质粒载体使用特异性抗体作为识别目标抗原的胞外结构域，缺口核心由跨膜结构域和缺口受体上的特异性酶切位点组成，转录因子 GAL4VP64 用作胞内结构域。当识别到目标抗原时，缺口上的酶切位点就会被相应的酶识别，从而水解和切割细胞间转录因子 GAL4VP64。另一种质粒载体携带转录因子 GAL4 的 DNA 识别/结合域 GAL4UAS，并相应地激活目标基因的最小启动子，GAL4VP64 被水解和切割后，将与结合域结合，激活后续基因的转录，从而表达 IL12 并将其分泌出细胞外。